Strategic Growth NxThera’s Convective Water Vapor Energy platform (Rezûm) is positioned for expansion beyond BPH into prostate and kidney cancers, indicating upsell opportunities to urology centers exploring novel minimally invasive therapies and broader endourology portfolios.

Clinical Excellence The Rezûm Center of Excellence program signals a commitment to clinical leadership and best-practice adoption, suggesting potential partnerships with high-volume urology groups for training, protocol standardization, and preferred-provider arrangements.

Acquisition Momentum Historical acquisition by Boston Scientific plus ongoing R&D focus highlights a procurement-ready environment; engage large medtech distributors and procurement channels looking to augment portfolios with proven endourology and energy-based therapies.

Market Readiness With a current revenue range of 1–10 million and a niche, innovative platform, there is an opportunity to target mid-to-large ambulatory surgery centers and specialized clinics seeking differentiated, patient-friendly BPH treatments to drive patient throughput.

Technology & Partnerships Tech stack and digital presence coupled with ongoing R&D for cancer applications suggest collaboration potential with healthcare IT vendors, telemedicine-enabled post-procedure care, and research partnerships to support clinical studies and data capture.